Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Votrient | Pazopanib hydrochloride | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
| Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Humira | Adalimumab | Arthritis, juvenile idiopathic | List with clinical criteria and/or conditions | Complete | ||
| Bystolic | Nebivolol | Hypertension | Do not list at the submitted price | Complete | ||
| Tecfidera | Dimethyl fumarate | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | ||
| Soliris | Eculizumab | Hemolytic Uremic Syndrome, Atypical | Do not list | Complete | ||
| Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Tykerb (in combination with Letrozole) | Lapatinib | Metastatic Breast Cancer | Do not reimburse | Complete |
Last Updated : May 19, 2024